What is BPC-157?

BPC-157 is a research peptide in the Healing & Recovery class. Synthetic pentadecapeptide; accelerates tendon-to-bone healing in preclinical models. It is studied at per-dose ranges of 250–500 mcg / day (1.75–3.5 mg weekly), administered 1–2× daily sc over cycles of 4–6 weeks. Supplied in Thailand by Thailand Peptides — Bangkok-based, research use only.

Pentadecapeptide derived from human gastric-juice BPC. Shown in rodent models to upregulate VEGF, modulate NO pathway, and accelerate tendon, ligament, and gut-mucosal repair.

Published and preclinical data are summarised below; dose ranges shown reflect protocols in the research literature and should be interpreted accordingly.

How does BPC-157 work?

Primary mechanism: Synthetic pentadecapeptide; accelerates tendon-to-bone healing in preclinical models. Research on BPC-157 implicates downstream effects on related signalling cascades, with magnitude and clinical relevance dependent on dose, timing, and individual pharmacogenomic factors.

Receptor binding affinity and post-receptor signalling for BPC-157 remain areas of active investigation; several proposed effects within the Healing & Recovery class are currently supported only by in-vitro or rodent data, and should be interpreted accordingly.

BPC-157 dosage & protocol

Reference protocol for BPC-157 (research context only, drawn from published literature):

  • Per dose: 250–500 mcg / day
  • Weekly total: 1.75–3.5 mg
  • Frequency: 1–2× daily SC
  • Cycle: 4–6 weeks

Stacking BPC-157

Commonly referenced pairing with BPC-157: TB-500. Stacking rationale should be grounded in complementary mechanisms, not additive speculation; interactions at shared receptors or enzymatic pathways should be accounted for. Both compounds in a BPC-157 stack are supplied by Thailand Peptides on the same order via the Bangkok research desk.

Contraindications

Active malignancy, undiagnosed tumours. Additional caution is warranted in individuals with hepatic or renal impairment, endocrine disorders, or concurrent pharmacotherapy affecting the pathways described above.

BPC-157 — common questions

What is BPC-157 and what is it used for in research?
BPC-157 is classified within the Healing & Recovery group. Pentadecapeptide derived from human gastric-juice BPC. Shown in rodent models to upregulate VEGF, modulate NO pathway, and accelerate tendon, ligament, and gut-mucosal repair. Research applications focus on the pathways outlined below. All references on this page describe published research only — BPC-157 is supplied for in-vitro and laboratory use, not for human consumption.
How does BPC-157 work?
Primary mechanism: Synthetic pentadecapeptide; accelerates tendon-to-bone healing in preclinical models. Downstream effects depend on dose, timing, and the biological system under investigation. Receptor binding and post-receptor signalling for BPC-157 remain areas of active study, and several proposed effects are supported only by preclinical data.
What is the typical BPC-157 research dose?
Published research protocols for BPC-157 describe per-dose ranges of 250–500 mcg / day, with a weekly total near 1.75–3.5 mg, administered 1–2× daily sc. Typical cycle: 4–6 weeks. These ranges reflect the literature and are not dosing recommendations for any individual.
Where can I buy BPC-157 in Thailand?
BPC-157 is supplied by Thailand Peptides, a Bangkok-based research-peptide supplier. Orders are placed directly via WhatsApp to the Bangkok research desk — no cart, no account, no forms. Pricing and shipping are provided on request. Open a line with the research desk →
How fast can BPC-157 be delivered in Thailand?
Same-week delivery across Thailand is standard for orders confirmed within business hours (GMT+7, Monday–Saturday). Bangkok metro deliveries typically arrive within 1–3 business days; other provinces within 3–5. Regional Southeast Asia shipping is available on request.

Citations

  1. Primary reference — peer-reviewed mechanism paper.
  2. Clinical trial data (where available).
  3. Pharmacokinetic profile — half-life and metabolism.
  4. Review of receptor binding affinities.